

# Angela Dm Kashuba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11874430/publications.pdf>

Version: 2024-02-01

52  
papers

2,483  
citations

201385

27  
h-index

197535

49  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2715  
citing authors

#	ARTICLE	IF	CITATIONS
1	The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans. <i>IScience</i> , 2022, , 104409.	1.9	4
2	Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 725-735.	0.5	4
3	S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1349-1356.	0.8	1
4	Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120844.	2.6	17
5	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020, 34, 1923-1931.	1.0	4
6	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 530-537.	0.9	17
7	Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 360-368.	1.3	19
8	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	1.5	5
9	Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 79-88.	0.9	11
10	Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. <i>Antiviral Therapy</i> , 2018, 23, 495-504.	0.6	6
11	Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10456.	1.8	43
12	HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 513-523.	0.5	27
13	Multimodal analysis of drug transporter expression in gastrointestinal tissue. <i>Aids</i> , 2017, 31, 1669-1678.	1.0	11
14	Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results. <i>Antiviral Therapy</i> , 2016, 21, 55-64.	0.6	6
15	Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract. <i>Antiviral Therapy</i> , 2015, 20, 795-803.	0.6	6
16	Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. <i>Aids</i> , 2015, 29, 331-337.	1.0	37
17	Pharmacokinetics of antiretrovirals in mucosal tissue. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 893-905.	1.5	30
18	Short Communication: Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1058-1064.	0.5	14

#	ARTICLE	IF	CITATIONS
19	Topical microbicides and HIV prevention in the female genital tract. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 603-615.	1.0	21
20	Female Sex Hormone Regulation of Tenofovir-diphosphate in Human Female Reproductive Tract (FRT) Cells in Culture. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A149-A150.	0.5	2
21	HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. <i>Virology</i> , 2014, 464-465, 253-263.	1.1	34
22	HIV pre-exposure prophylaxis trials: the road to success. <i>Clinical Investigation</i> , 2013, 3, 295-308.	0.0	16
23	Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 260-266.	0.9	37
24	Antiretroviral Pharmacology in Mucosal Tissues. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S240-S247.	0.9	51
25	Differential penetration of raltegravir throughout gastrointestinal tissue. <i>Aids</i> , 2013, 27, 1413-1419.	1.0	55
26	Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. <i>Antiviral Therapy</i> , 2013, 18, 1005-1013.	0.6	32
27	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. <i>Pharmacogenomics</i> , 2012, 13, 113-121.	0.6	27
28	Antiviral agents and HIV prevention. <i>Aids</i> , 2012, 26, 1585-1598.	1.0	89
29	Pre-exposure prophylaxis for HIV prevention: how to predict success. <i>Lancet, The</i> , 2012, 379, 2409-2411.	6.3	64
30	Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 451-462.	1.4	39
31	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. <i>Lancet, The</i> , 2011, 378, 279-281.	6.3	220
32	Combined Oral Contraceptives and Antiretroviral PK/PD in Malawian Women: Pharmacokinetics and Pharmacodynamics of a Combined Oral Contraceptive and a Generic Combined Formulation Antiretroviral in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e40-e43.	0.9	24
33	HIV-1 treatment as prevention: the good, the bad, and the challenges. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 1.	1.5	66
34	Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. <i>Antiviral Therapy</i> , 2010, 15, 83-90.	0.6	12
35	Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 92-96.	1.2	14
36	Measurement of antiretroviral drugs in the lungs of HIV-infected patients. <i>HIV Therapy</i> , 2010, 4, 247-251.	0.6	24

#	ARTICLE	IF	CITATIONS
37	A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. <i>Talanta</i> , 2009, 79, 1372-1378.	2.9	46
38	An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. <i>Analytica Chimica Acta</i> , 2008, 628, 204-213.	2.6	12
39	Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1. <i>Annals of Internal Medicine</i> , 2007, 146, 591.	2.0	202
40	Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. <i>Aids</i> , 2007, 21, 1899-1907.	1.0	177
41	Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. <i>Aids</i> , 2007, 21, 59-64.	1.0	24
42	High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 1562-1567.	1.4	35
43	Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 52-60.	0.9	172
44	Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. <i>Aids</i> , 2005, 19, 145-152.	1.0	53
45	Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 822, 201-208.	1.2	90
46	High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 241-247.	1.2	58
47	Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 791, 137-147.	1.2	82
48	Kaletra (Lopinavir/Ritonavir). <i>Annals of Pharmacotherapy</i> , 2002, 36, 1193-1203.	0.9	93
49	Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 79-88.	1.2	30
50	Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 540-551.	2.3	86
51	Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 269-277.	2.3	105
52	Physiological Changes During the Menstrual Cycle and Their Effects on the Pharmacokinetics and Pharmacodynamics of Drugs. <i>Clinical Pharmacokinetics</i> , 1998, 34, 203-218.	1.6	129